List of Artificial Intelligence Companies in Oregon - 4

Birch Biosciences uses Artificial Intelligence, bioinformatics, and high-throughput screening techniques to effectively engineer enzymes for recycling plastic.

Micro Systems Engineering, Inc. (MSEI), with its main office in Lake Oswego, Oregon, is is a pioneer in developing innovative implantable medical device technologies and devices that save and enhance the quality of life for millions of patients across the globe. With more than 40 years of experience in design and manufacturing active implantable medical devices, our continuing success is based on our company's core values – innovation, quality, reliability, integrity, teamwork, and undisputed expertise – thus enabling us to inspire confidence and trust in physicians and patients worldwide. MSEI has two main divisions, Operations and System Design & Development. With over 400 technical staff including physicists, electrical, software, biomedical and materials engineers, MSEI employs an elite team of the brightest minds in the medical technology industry. The Operations division is a specialist in medical microelectronics manufacturing including development, design, testing, supply chain and system integration for medical technology, in particular for active implants in the area of CRM (cardiac rhythm management) and other medical applications. The Operations division is dedicated to the innovative design and quality construction of electronic modules used in implantable medical devices. System Design & Development is the innovation center for next generation class III active implants. This includes full system design, clinical research, hardware and software, as well as the design and test of application-specific integrated circuits (ASICs). The resulting products deliver life-saving therapies to patients accurately and reliably across the globe.

Rewire AI is a computer vision and machine learning company that specializes in biomedical imaging services, offering a cloud-based artificial intelligence inference engine for clinical and research applications.

UbiVac is a clinical stage biotech engaged in research and development, and manufacture, of therapeutic immune activators, vaccines and cellular immunotherapies to combat cancer. Used in combination with other immunotherapies, UbiVac’s patented technologies have proven highly effective at improving survival and apparent cure in difficult to treat animal cancers (PMID: 27874054; PMID: 31747946; PMID: 22068657). UbiVac believes that the explanation for this effectiveness lies in several high impact publications from 2021 identifying a previously unknown class of shared non-mutated cancer neoantigens that make up as much as 25% of the antigens on cancer cells (PMID: 33740418; PMID: 33691108; PMID: 34663921). As the non-mutated shared cancer neoantigens are short-lived proteins, the majority are expected to be contained in UbiVac’s DPV-001. Importantly, these findings help explain why UbiVac’s immunotherapy provided cross-protective cancer immunity in preclinical models, something that had not been observed in 50 years of study (PMID: 21810919). These remarkable studies raised the possibility of off-the-shelf Universal Cancer Vaccines (PMID: 33852826). UbiVac has completed an NCI-funded phase I/II adjuvant trial of its lead agent, DPV-001. This trial met its endpoints, determined safety, identified drug formulation, and demonstrated proof-of-concept. Based on these data UbiVac partnered with the Providence Cancer Institute and Incyte on a first-in-human immunotherapy trial of UbiVac’s DPV-001, anti-GITR and anti-PD-1 for advanced HNSCC. The first patients were treated in Q4 2021, and preliminary immunological monitoring data will be presented at AACR in April 2022. UbiVac also has a pipeline of cellular therapies under development. Given that UbiVac’s CEO and CSO, together, have 55+ years of experience with preclinical and clinical studies of adoptive immunotherapy, UbiVac is well positioned to bring their innovative cellular therapy platforms to the clinic.